Mesoblast Limited
NASDAQ:MESOBiotechnology
+$0.26 today
- Market cap
- $1.51B
- Beta
- 0.79
- P/E (TTM)
- -23.6
- EPS (TTM)
- -$0.06
Volume 0.13M
Average 0.21M
MESO Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Mesoblast LimitedNASDAQ: MESO
Free Cash Flow · Q4 FY2026 · quarter ended Jun 2026
Free cash flow declines year over year
Q4 FY2026 free cash flow of $6.95M (cash outflow) fell 53.5% year over year, behind the -12.7% change in trailing-twelve-month free cash flow. Sequentially, it rose 55.7% from the prior quarter. Over 3 fiscal years it compounded at -11.1% a year.
Context
- Free cash flow amounted to 37.0% of revenue in FY2026, down 257.7 pp from a year earlier.
- Free cash flow grew in size in 1 of the last 3 fiscal years.
- FY2026 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -53.5% toward the trailing-twelve-month pace of -12.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2026
- (44.73M) USD
- Year-over-year change
- +11.8%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | (44.73M) | +11.8% |
| FY2025 | 2025-06-30 | (50.68M) | -3.9% |
| FY2024 | 2024-06-30 | (48.79M) | +23.3% |
| FY2023 | 2023-06-30 | (63.58M) | +3.7% |
| FY2022 | 2022-06-30 | (66.01M) | — |
Free Cash Flow vs competitors
How MESO compares with its peers on the latest reported figures
- MESO's LTM Jun 2026 free cash flow of $42.36M is the 4th largest of the 6 companies compared; the peer median is $108.09M.
- Its year-over-year change of -12.7% is the 5th highest of 6, against a peer median of +70.1%.
- Free cash flow amounts to 35.2% of revenue for MESO, versus a peer median of 100.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $320.88M | +70.1% | -9.1% | 23.6% | |
| LTM Mar 2026 | $113.96M | +141.6% | — | — | |
| LTM Mar 2026 | $108.09M | -13.6% | -26.6% | 1711.4% | |
| LTM Jun 2026 | $42.36M | -12.7% | -11.1% | 35.2% | |
| LTM Mar 2026 | $22.3M | -1.4% | — | 150.9% | |
| LTM Dec 2025 | $13.25M | +102.0% | -54.8% | 49.9% | |
| Peer median (excluding MESO) | $108.09M | +70.1% | -26.6% | 100.4% | |
Competitors are the stored peer set for MESO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Net Income | (91.35M) | (81.89M) | (87.96M) | (102.14M) | 0 |
| Depreciation & Amortization | 4.38M | 4.11M | 4.67M | 6.4M | 0 |
| Deferred Income Tax | (235K) | (212K) | (191K) | 330K | 0 |
| Stock-Based Compensation | 5.54M | 3.66M | 5.87M | 22.09M | 0 |
| Change in Working Capital | 4.87M | (2.47M) | (2.63M) | (3.04M) | 0 |
| Accounts Receivables | 140K | (118K) | (15.47M) | 6.29M | 0 |
| Inventory | 0 | 0 | 0 | 826K | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 4.73M | (2.35M) | 12.84M | (10.16M) | 0 |
| Other Non-Cash Items | 11.02M | 13.54M | 31.78M | 26.41M | (43.83M) |
| Operating Cash Flow | (65.78M) | (63.27M) | (48.46M) | (49.95M) | (43.83M) |
| Capital Expenditures | (232K) | (314K) | (331K) | (730K) | (898K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (125K) |
| Sales of Investments | 0 | 120K | 234K | 241K | 0 |
| Other Investing Activities | (75K) | 120K | (60K) | 559K | (65K) |
| Investing Cash Flow | (232K) | (194K) | (97K) | 120K | (1.02M) |
| Debt Repayment | (6.33M) | (2.66M) | (13.52M) | (9.77M) | (5.94M) |
| Common Stock Issued | 209K | 88.64M | 65.41M | 161.21M | 14.24M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.75M) | (11.48M) | (11.63M) | (4.1M) | (23.64M) |
| Financing Cash Flow | (9.87M) | 74.5M | 40.25M | 147.34M | (15.33M) |
| Effect of Forex Changes | (550K) | (168K) | (55K) | 1.09M | 1.55M |
| Net Change in Cash | (76.43M) | 10.87M | (8.36M) | 98.59M | (58.64M) |
| Free Cash Flow | (66.01M) | (63.58M) | (48.79M) | (50.68M) | (44.73M) |
Mesoblast Limited
NASDAQ:MESO
Intrinsic Alpha fair value
Locked
Current Price
$11.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.